X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SUN PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SUN PHARMA DIVIS LABORATORIES/
SUN PHARMA
 
P/E (TTM) x 34.5 35.0 98.6% View Chart
P/BV x 6.7 2.7 247.1% View Chart
Dividend Yield % 0.7 0.5 143.7%  

Financials

 DIVIS LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
SUN PHARMA
Mar-18
DIVIS LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,142701 163.0%   
Low Rs533433 123.1%   
Sales per share (Unadj.) Rs146.6110.4 132.8%  
Earnings per share (Unadj.) Rs33.011.0 300.9%  
Cash flow per share (Unadj.) Rs38.417.2 222.9%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.20.4 338.4%  
Book value per share (Unadj.) Rs222.8158.8 140.3%  
Shares outstanding (eoy) m265.472,399.26 11.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.75.1 111.3%   
Avg P/E ratio x25.351.6 49.1%  
P/CF ratio (eoy) x21.832.9 66.3%  
Price / Book Value ratio x3.83.6 105.3%  
Dividend payout %30.318.2 166.1%   
Avg Mkt Cap Rs m222,3181,360,021 16.3%   
No. of employees `00010.817.8 60.5%   
Total wages/salary Rs m4,56153,671 8.5%   
Avg. sales/employee Rs Th3,616.014,890.9 24.3%   
Avg. wages/employee Rs Th423.83,017.1 14.0%   
Avg. net profit/employee Rs Th814.91,480.6 55.0%   
INCOME DATA
Net Sales Rs m38,915264,895 14.7%  
Other income Rs m1,1348,388 13.5%   
Total revenues Rs m40,049273,282 14.7%   
Gross profit Rs m12,61756,081 22.5%  
Depreciation Rs m1,42514,998 9.5%   
Interest Rs m135,176 0.3%   
Profit before tax Rs m12,31344,295 27.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m3,5438,452 41.9%   
Profit after tax Rs m8,77026,338 33.3%  
Gross profit margin %32.421.2 153.1%  
Effective tax rate %28.819.1 150.8%   
Net profit margin %22.59.9 226.7%  
BALANCE SHEET DATA
Current assets Rs m45,351316,359 14.3%   
Current liabilities Rs m6,507198,643 3.3%   
Net working cap to sales %99.844.4 224.6%  
Current ratio x7.01.6 437.6%  
Inventory Days Days12795 133.6%  
Debtors Days Days95108 88.3%  
Net fixed assets Rs m21,160213,178 9.9%   
Share capital Rs m5312,399 22.1%   
"Free" reserves Rs m58,625378,606 15.5%   
Net worth Rs m59,156381,006 15.5%   
Long term debt Rs m017,721 0.0%   
Total assets Rs m67,832643,028 10.5%  
Interest coverage x926.89.6 9,696.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.4 139.3%   
Return on assets %12.94.9 264.2%  
Return on equity %14.86.9 214.5%  
Return on capital %20.810.0 207.9%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35940,816 79.3%   
Fx outflow Rs m9,04230,143 30.0%   
Net fx Rs m23,31710,673 218.5%   
CASH FLOW
From Operations Rs m7,75939,072 19.9%  
From Investments Rs m-4,783-33,708 14.2%  
From Financial Activity Rs m-3,142-15,393 20.4%  
Net Cashflow Rs m-166-7,359 2.3%  

Share Holding

Indian Promoters % 52.0 63.7 81.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 5.1 230.0%  
FIIs % 19.0 23.0 82.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 8.3 207.2%  
Shareholders   31,796 133,026 23.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  PANACEA BIOTECH  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open on a Positive Note; Realty & Auto Stocks Lead(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.2% while the Hang Seng is up 1.6%.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Dec 12, 2018 11:23 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - STRIDES PHARMA SCIENCE COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS